Logo-bi
Short Communication
Morteza Mahmoudi, Mingming Zhao, Yuka Matsuura, Sophie Laurent, Phillip C. Yang, Daniel Bernstein, Pilar Ruiz-Lozano*, Vahid Serpooshan*
Bioimpacts. 2016;6(2): 111-115. doi: 10.15171/bi.2016.16
PMCID: PMC4981249     PMID: 27525229     Scopus ID: 84983548259    
Original Research
Soheila Rostami ORCID, Farzaneh Tafvizi* ORCID, Hamid Reza Kheiri Manjili
BioImpacts. 2022;12(4): 301-313. doi: 10.34172/bi.2021.23337
PMCID: PMC9376161     PMID: 35975200     Scopus ID: 85138644192    
The findings suggest that F-Lys-TMX NPs are more effective and have the potential for cell proliferation inhibition and apoptosis induction compared to the TMX. Hence, F-Lys-TMX NPs can be considered as an anti-cancer agent against MCF-7 breast cancer cells.


As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate (2024): 20% 
Publication fee: Free of charge

Indexing/Abstracting Info
PubMedPubMed Central; Scopus; Science Citation Index Expanded; Google Scholar;   SJR; Essential Science IndicatorsEmbase; EBSCOhost; CAS: DOAJSHERPA/RoMEO
Member of COPE
Follower of ICMJE
Permission: Creative Commons